Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study To Assess The Pharmacokinetics, Safety, And Tolerability of Intravenous ACHN-490 Injection in Volunteers With Varying Degrees of Renal Dysfunction Compared to Healthy Volunteers.

Next Previous
Trial Profile

A Phase 1 Study To Assess The Pharmacokinetics, Safety, And Tolerability of Intravenous ACHN-490 Injection in Volunteers With Varying Degrees of Renal Dysfunction Compared to Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plazomicin (Primary)
  • Indications Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Achaogen

Most Recent Events

  • 22 Jan 2019 Results of pooled analysis assessing the population pharmacokinetics for Plazomicin from 7 studies :NCT00822978, NCT01034774,NCT01462136,NCT01514929,NCT01096849,NCT01970371 and NCT02486627 were published in the Antimicrobial Agents and Chemotherapy
  • 01 Oct 2018 Results published in the Antimicrobial Agents and Chemotherapy
  • 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top